Orange Book product · Generic (ANDA)
APIXABAN
APIXABAN
At a glance
Feb 27, 2023
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Feb 27, 2023
3 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
APIXABAN
Strength
2.5MG
Dosage form
TABLET
Route
ORAL
TE code
Not listed
Application
ANDA 210185
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of APIXABAN
- 2025ELIQUIS SPRINKLEBrand (NDA)
NDA 220073 · BRISTOL
- 2025ELIQUISBrand (NDA)
NDA 202155 · BRISTOL MYERS SQUIBB
- 2025APIXABANGeneric (ANDA)
ANDA 210067 · MACLEODS PHARMS LTD
- 2025APIXABANGeneric (ANDA)
ANDA 209810 · IMPAX
- 2024APIXABANGeneric (ANDA)
ANDA 210156 · TORRENT
- 2024APIXABANGeneric (ANDA)
ANDA 210091 · APOTEX
- 2023APIXABANGeneric (ANDA)
ANDA 210066 · HETERO LABS LTD V
- 2023APIXABANGeneric (ANDA)
ANDA 210026 · AUROBINDO PHARMA LTD
- 2021APIXABANGeneric (ANDA)
ANDA 209845 · BRECKENRIDGE
- 2020APIXABANGeneric (ANDA)
ANDA 209898 · REGCON HOLDINGS
- 2020APIXABANGeneric (ANDA)
ANDA 210180 · ACCORD HLTHCARE
- 2020APIXABANGeneric (ANDA)
ANDA 210152 · BIONPHARMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
